Active Filter(s):
Details:
This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN®) for the innovative ultrasound-assisted delivery catheter of Vensica.
Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Urology Product Name: Xeomin
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Merz Therapeutics
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Partnership February 07, 2022